Management

Fouzia Laghrissi-Thode, M.D.

Chief Executive Officer

Fouzia Laghrissi-Thode has more than 20 years of pharmaceutical industry leadership experience including leading the dalcetrapib Dal-HEART program at F. Hoffmann-La Roche. Most recently, Dr. Laghrissi-Thode was Vice-President at AstraZeneca of the US Renal-Cardiology Therapeutic Area. Her previous roles include Head of the Cardiovascular and Metabolism Therapeutic Area, Global Product and Portfolio Strategy at AstraZeneca and Roche. She has a wealth of experience in US and Europe through working in clinical development, global strategic marketing, business development, licensing and M&A in a variety of therapeutic areas including cardiovascular, diabetes, renal and the central nervous system. She has served as a board member of the Healthcare Businesswomen’s Association (HBA) Europe and was recognized by HBA in 2012 for her work in developing and promoting women leadership in healthcare. She served as a faculty member at the University of Pittsburgh Medical Center,  Western Psychiatric Institute and Clinic. Dr. Laghrissi-Thode is board certified in Psychiatry and holds Doctorate in Medicine from the University of Tours School of Medicine in France.

Donald M. Black, M.D.

Chief Medical Officer

Donald M. Black has over 25 years of experience, during which he has held various senior leadership positions working in clinical development. Dr. Black served as general manager of advanced diabetes care at Becton Dickinson, global leader of research and development as well as general manager of molecular imaging at GE Medical Diagnostics, vice president of global strategic development at Merck and Co, and vice president of clinical research at Parke-Davis, where he was responsible for the clinical development of Lipitor. Dr. Black has served on multiple boards of directors as well as scientific boards, and has over 150 publications, presentations and chapters. His academic appointments include associate professor of pediatric cardiology at the University of Michigan, professor of medicine at the University of Cincinnati, and adjunct professor of medicine, National University of Ireland at Galway. Dr. Black earned his M.D. from University of Michigan Medical School and his MBA University of Cincinnati College of Business.

Michael Dixon, C.P.A., C.A.

Chief Financial Officer

Michael Dixon has over 20 years of experience working in an executive role for venture-backed companies. He was chief financial officer of Gemin X Pharmaceuticals where he structured and negotiated equity financings leveraged with venture debt and other forms of non-dilutive capital to fund the company’s Canadian and US operations over an 11-year period. Gemin X was successfully sold to Cephalon (now Teva), at the time one of the largest private biotech deals in Canada. Mr. Dixon was Interim COO and vice president of finance at Morphometrix Technologies, a medical device company specialized in the automation of cervical cancer screening. Mr. Dixon began his career at Price Waterhouse with a focus on compliance services for entrepreneurial businesses, strategic financial modeling and management information systems. Mr. Dixon received his Bachelor of Commerce degree from the University of Toronto and his Chartered Accountant designation while at Price Waterhouse.

Peter Schuepbach

Vice President, Technical Operations

Peter Schuepbach has more than 30 years of experience in operational management and consulting for major Engineering, Pharma and Biotech companies. He led the development and the implementation of Supply Chain Strategies in several global organizations. Prior to joining DalCor, he was Executive Vice President for Technical Operations at Finox Biotech, an innovative Swiss start-up company. Mr. Schuepbach held the position of Global Supply Chain Leader at Roche Pharma. In this function he was responsible for building the commercial supply chain and launching many of Roche’s major brand product including the launch readiness of the supply chain of dalcetrapib. In 1994 he joined as Head of Supply Chain Planning and Control for the Roche Diagnostics Division. Mr. Schuepbach received his Bachelor of Science in Engineering from the Bern University of Applied Sciences and is an APICS Certified Production and Inventory Manager (CPIM).

Therese Heinonen, D.V.M.

Vice President, Clinical Operations

Therese Heinonen has accumulated over 27 total years of research experience, with 25 years dedicated to clinical research in the areas of cardiology, endocrinology, neurology, and oncology. Dr. Heinonen was a member of the Parke-Davis and Pfizer Global Research and Development cardiovascular senior management teams where she made significant contributions to the clinical development of several products including most notably, Lipitor. Dr. Heinonen has authored over 50 publications and managed over 30 clinical trials, many of which have focused on cardiovascular biomarkers and imaging technologies. Dr. Heinonen has worked as a consultant to government institutions, academic institutions, pharmaceutical companies, biotechnology organizations and diagnostic companies. In 2003, Dr. Heinonen began organizing the annual Cardiovascular Biomarkers and Surrogate Endpoints Symposium and in 2006 co-founded the International Partnership for Critical Markers of Disease. Dr. Heinonen has also founded or significantly contributed to the initiation of several start-up companies. Dr. Heinonen is a graduate of Michigan State University College of Veterinary Medicine and received training in molecular biology at Merck Research Laboratories.

Bruno Pirovino-Zuercher

Director, Swiss Branch

Bruno Pirovino-Zuercher has more than 20 years of managerial experience and consulting for biotech and pharmaceutical companies. Mr. Pirovino-Zürcher is director at the Swiss branch of DalCor and oversees all aspects of the development of dalcetrapib. His international career path encompassed several years in accounting, finance, business and management roles at IMS Health, Pliva International, Eisai Pharmaceuticals and Johnson & Johnson. He holds a bachelor’s degree in business administration and an executive master’s degree in corporate finance from the Lucerne University of Applied Sciences and Arts as well as a CAS in global entrepreneurship from the University of Basel, Switzerland.